Form 4: CG Oncology Director Exercises Options and Sells Shares Under Pre-Arranged Plan

CG Oncology Director Leonard Post exercised 2,000 stock options at $0.60 per share and simultaneously sold the same number of shares at $28.00 per share, as part of a pre-arranged trading plan.

Summary

• Leonard E. Post, a Director of CG Oncology, Inc. (CGON), reported transactions on July 17, 2025.
• Post exercised 2,000 Director Stock Options at an exercise price of $0.60 per share.
• Concurrently, Post sold 2,000 shares of Common Stock at a price of $28.00 per share.
• The sales were conducted under a Rule 10b5-1 trading plan established on September 6, 2024.
• Following these transactions, Post's direct beneficial ownership of the reported common stock is 0 shares.
• Post retains 126,077 derivative securities (stock options) after these transactions.
• The exercised options were fully vested.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) under a pre-arranged plan, which is common for directors managing their equity compensation. It doesn't inherently signal strong positive or negative sentiment about the company's future, though a sale reduces direct ownership.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to immediate market conditions.
• The exercise price of the options ($0.60) is significantly lower than the sale price ($28.00), indicating a substantial gain for the director on these specific shares.

Negatives

• A director selling shares, even under a pre-arranged plan, could be perceived negatively by some investors as it reduces their direct equity stake in the company.

Future Outlook

The document does not provide forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a director's personal financial planning related to their equity compensation.

Comparison to Industry Standards

• This document reports a standard insider transaction (exercise and sell) under a Rule 10b5-1 plan, which is a common practice for executives and directors managing their equity compensation.
• There are no specific comparable companies, projects, or results mentioned in this transactional report to assess against industry standards.

Stakeholder Impact

• Shareholders: The sale by a director, while part of a pre-arranged 10b5-1 plan, could be interpreted in various ways by investors. It slightly increases the public float of shares.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director, Leonard Post, Rule 10b5-1 Plan, Beneficial Ownership